Therapeutic Efficiency of Ranibizumab and 4-Methyl Catechol on The Progression of Streptozotocin-Induced Diabetic Retinopathy in Rats: Involving Vascular Endothelial Growth Factor-A and Nerve Growth Factor
Elsayed, E., El-Saadany, A., Elwan, W., Abdin, A., Abd Elmonem, F. (2023). Therapeutic Efficiency of Ranibizumab and 4-Methyl Catechol on The Progression of Streptozotocin-Induced Diabetic Retinopathy in Rats: Involving Vascular Endothelial Growth Factor-A and Nerve Growth Factor. EKB Journal Management System, (), -. doi: 10.21608/bfsa.2023.244738.1956
Eman Elsayed; Amira El-Saadany; Walaa Elwan; Amany Abdin; Fleur Abd Elmonem. "Therapeutic Efficiency of Ranibizumab and 4-Methyl Catechol on The Progression of Streptozotocin-Induced Diabetic Retinopathy in Rats: Involving Vascular Endothelial Growth Factor-A and Nerve Growth Factor". EKB Journal Management System, , , 2023, -. doi: 10.21608/bfsa.2023.244738.1956
Elsayed, E., El-Saadany, A., Elwan, W., Abdin, A., Abd Elmonem, F. (2023). 'Therapeutic Efficiency of Ranibizumab and 4-Methyl Catechol on The Progression of Streptozotocin-Induced Diabetic Retinopathy in Rats: Involving Vascular Endothelial Growth Factor-A and Nerve Growth Factor', EKB Journal Management System, (), pp. -. doi: 10.21608/bfsa.2023.244738.1956
Elsayed, E., El-Saadany, A., Elwan, W., Abdin, A., Abd Elmonem, F. Therapeutic Efficiency of Ranibizumab and 4-Methyl Catechol on The Progression of Streptozotocin-Induced Diabetic Retinopathy in Rats: Involving Vascular Endothelial Growth Factor-A and Nerve Growth Factor. EKB Journal Management System, 2023; (): -. doi: 10.21608/bfsa.2023.244738.1956

Therapeutic Efficiency of Ranibizumab and 4-Methyl Catechol on The Progression of Streptozotocin-Induced Diabetic Retinopathy in Rats: Involving Vascular Endothelial Growth Factor-A and Nerve Growth Factor

Bulletin of Pharmaceutical Sciences Assiut University
Articles in Press, Accepted Manuscript, Available Online from 22 November 2023  XML
Document Type: Original Article
DOI: 10.21608/bfsa.2023.244738.1956
View on SCiNiTO View on SCiNiTO
Authors
Eman Elsayed email 1; Amira El-Saadanyorcid 1; Walaa Elwan2; Amany Abdin1; Fleur Abd Elmonem1
1Pharmacology Department, Faculty of Medicine, Tanta University, Tanta, Egypt
2Histology Department, Faculty of Medicine, Tanta University, Egypt
Abstract
Purpose: Diabetic retinopathy (DR) is a chronic microvascular diabetic complication leading to visual loss. Ranibizumab (RBZ) is a monoclonal antibody inhibiting VEGF-A, approved for DR treatment. 4-Methyl catechol (4MC) is a potent NGF stimulant & possesses a neuroprotective effect in neuronal diseases. The aim of this study was to evaluate the role of 4MC in comparison to RBZ in the progression of streptozotocin (STZ) induced-diabetic retinopathy in albino rats. Methods: This experiment was performed on 40 albino rats divided equally into: (normal control, untreated DR, RBZ treated intravitreally & 4MC treated intravitreally). Results: The untreated DR group revealed a significant elevation of fasting serum glucose, VEGF-A, histopathological score & IHC score of Tie-2, and a significant decrease in NGF, and IHC of Bcl-2 versus the normal control group. Treatment with either RBZ or 4MC produced significant improvement in the forementioned parameters when compared to the untreated DR group. Conclusion: RBZ and 4MC are effective in the progression of STZ-induced DR via inhibition of VEGF-A and stimulation of NGF respectively.
Keywords
Diabetic retinopathy; Streptozotocin; Ranibizumab; 4-Methyl catechol
Statistics
Article View: 88